Developing a Dissociative Nanocontainer for Peptide Drug Delivery.

Area of Science:

• Biotechnology
• Nanotechnology
• Pharmacology

Background:

• Bioactive peptides offer potent, selective therapeutic potential, particularly for neurological disorders and pain.
• Current peptide therapeutics face delivery challenges, often requiring invasive methods, limiting widespread clinical use.
• Viral capsids, like P22 bacteriophage, can be engineered as nanocontainers for drug delivery.

Purpose of the Study:

• To develop a tunable nanocontainer system for packaging and controlled release of bioactive peptides.
• To address the challenge of releasing encapsulated peptides at target sites for enhanced therapeutic efficacy.
• To establish a proof-of-concept for a triggerable peptide drug delivery system utilizing viral nanocontainers.

Main Methods:

• Modification of P22 bacteriophage capsid to create tunable nanocontainers for peptide encapsulation.
• Conjugation of a Ring Opening Metathesis Polymerization (ROMP) substrate (norbornene) to the exterior of loaded nanocontainers.
• Utilizing Grubbs II Catalyst to initiate ROMP, triggering nanocontainer disassembly and peptide release under physiological conditions.

Main Results:

• Demonstrated successful encapsulation and translocation of analgesic peptides across blood-brain-barrier (BBB) models using P22 nanocontainers.
• Initiated ROMP reaction on modified P22 nanocontainers, leading to their disassembly.
• Initial characterization of ROMP-triggered cargo peptide release from the nanocontainers.

Conclusions:

• The P22 bacteriophage capsid can be engineered into a functional nanocontainer for peptide drug delivery.
• ROMP provides a viable mechanism to trigger nanocontainer disassembly and controlled peptide release under physiological conditions.
• This work presents a promising, triggerable viral nanocontainer system for peptide therapeutics, advancing non-invasive drug delivery strategies.